de Angelis Paula M, Fjell Bjørg, Kravik Katherine L, Haug Terje, Tunheim Siv H, Reichelt Wenche, Beigi Marzieh, Clausen Ole Petter, Galteland Eivind, Stokke Trond
Institute of Pathology, Norwegian National Hospital, N-0027 Oslo, Norway.
Int J Oncol. 2004 May;24(5):1279-88.
5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer, but resistance to 5-FU remains a major obstacle to successful therapy. We generated 5-FU-resistant derivatives of the HCT116 human colon cancer cell line by serial passage of these cells in the presence of increasing 5-FU concentrations in an attempt to elucidate the biological mechanisms involved in resistance to 5-FU. Two resultant resistant derivatives, HCT116 ResB and ResD, were characterized for resistance phenotypes, genotypes, and gene expression using cells maintained long-term in 5-FU-free media. Compared to parental HCT116 cells that respond to 5-FU challenge by inducing high levels of apoptosis, ResB and ResD derivatives had significantly reduced apoptotic fractions when transiently challenged with 5-FU. ResB and ResD cells were respectively 27- and 121-fold more resistant to 5-FU, had increased doubling times, and significantly increased plating efficiencies compared to the parental cells. Both resistant derivatives retained the wild-type TP53 genotype, TP53 copy number and CGH profile characteristic of the parental line. Alterations in gene expression in the resistant derivatives compared to the parental line were assessed using oligonucleotide microarrays. Overall, the 5-FU-resistant derivatives were characterized by reduced apoptosis and a more aggressive growth phenotype, consistent with the observed up-regulation of apoptosis-inhibitory genes (e.g., IRAK1, MALT1, BIRC5), positive growth-regulatory genes (e.g., CCND3, CCNE2, CCNF, CYR61), and metastasis genes (e.g., LMNB1, F3, TMSNB), and down-regulation of apoptosis-promoting genes (e.g., BNIP3, BNIP3L, FOXO3A) and negative growth-regulatory genes (e.g., AREG, CCNG2, CDKN1A, CDKN1C, GADD45A). 5-FU metabolism-associated genes (e.g., TYMS, DTYMK, UP) and DNA repair genes (e.g., FEN1, FANCG, RAD23B) were also up-regulated in one or both resistant derivatives, suggesting that the resistant derivatives might be able to overcome both 5-FU inhibition of thymidylate synthase and the DNA damage caused by 5-FU, respectively. Development of 5-FU resistance thus appears to encompass deregulation of apoptosis-, proliferation-, DNA repair-, and metastasis-associated regulatory pathways.
5-氟尿嘧啶(5-FU)是治疗转移性结直肠癌的首选化疗药物,但对5-FU的耐药性仍然是成功治疗的主要障碍。我们通过在不断增加的5-FU浓度下连续传代培养HCT116人结肠癌细胞系,获得了对5-FU耐药的衍生物,试图阐明与5-FU耐药相关的生物学机制。使用在无5-FU培养基中长期培养的细胞,对产生的两种耐药衍生物HCT116 ResB和ResD的耐药表型、基因型和基因表达进行了表征。与通过诱导高水平凋亡对5-FU挑战作出反应的亲本HCT116细胞相比,ResB和ResD衍生物在用5-FU短暂刺激时凋亡分数显著降低。与亲本细胞相比,ResB和ResD细胞对5-FU的耐药性分别高27倍和121倍,倍增时间增加,平板接种效率显著提高。两种耐药衍生物均保留了亲本细胞系的野生型TP53基因型、TP53拷贝数和比较基因组杂交图谱特征。使用寡核苷酸微阵列评估了耐药衍生物与亲本细胞系相比的基因表达变化。总体而言,5-FU耐药衍生物的特征是凋亡减少和生长表型更具侵袭性,这与观察到的凋亡抑制基因(如IRAK1、MALT1、BIRC5)、正向生长调节基因(如CCND3、CCNE2、CCNF、CYR61)和转移基因(如LMNB1、F3、TMSNB)的上调,以及凋亡促进基因(如BNIP3、BNIP3L、FOXO3A)和负向生长调节基因(如AREG、CCNG2、CDKN1A、CDKN1C、GADD45A)的下调一致。5-FU代谢相关基因(如TYMS、DTYMK、UP)和DNA修复基因(如FEN1、FANCG、RAD23B)在一种或两种耐药衍生物中也上调,这表明耐药衍生物可能分别能够克服5-FU对胸苷酸合成酶的抑制和5-FU引起的DNA损伤。因此,5-FU耐药的发展似乎涉及凋亡、增殖、DNA修复和转移相关调节通路失调。